Felix Sedlmayer

Publications (7)29.51 Total impact

• Article: Progress in Radio-Oncology VIII. Proceedings of the 8th International Meeting on Progress in Radio-Oncology ICRO/OGRO 8.

  Peter Lukas, Karin Kapp, Richard Pötter, Felix Sedlmayer
  Strahlentherapie und Onkologie 01/2008; 183 Spec No 2:1-2. · 3.56 Impact Factor
• Article: Irradiation with and without razoxane in the treatment of incompletely resected or inoperable recurrent rectal cancer. Results of a small randomized multicenter study.

  Walter Rhomberg, Josef Hammer, Felix Sedlmayer, Helmut Eiter, Dieter Seewald, Barbara Schneider
  [show abstract] [hide abstract]
  ABSTRACT: In an earlier phase II study, irradiation together with razoxane was shown to improve local control in recurrent rectal cancer. Therefore, the Austrian Society of Radiooncology (OGRO) initiated a randomized controlled trial in 1992 to compare this combined treatment versus radiation therapy alone. Between 1992 and 1999, 36 patients with localized recurrences of rectal cancer were randomized to receive radiotherapy without (group A) or with razoxane (group B). The prognostic variables of the two groups were similar except for a longer median latency period from initial surgery to local recurrence in group A. High-energy photons with daily fractions between 170 and 200 cGy were used. The median total radiation dose was 60 Gy in each group. The patients in group B received a median razoxane dose of 9.6 g (range, 5-12 g). Main outcome measures were local control, overall survival, and toxicity. The combined treatment with razoxane increased the local control rate compared to radiotherapy alone (39% vs. 8%; p = 0.05). The median survival time was not different between the groups (20 months each). No patient in arm A but four of 18 patients in arm B survived 5 years. Acute toxic effects were of moderate degree in both groups. There were no substantial differences as to late side effects. Radiotherapy together with razoxane is superior to radiation treatment alone in recurrent rectal cancer as far as local control is concerned. In some patients, long-term survival was achieved with razoxane and radiotherapy.
  Strahlentherapie und Onkologie 08/2007; 183(7):380-4. · 3.56 Impact Factor
• Source

  Available from: Leonore Handl-Zeller

  Article: Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer.

  Richard Pötter, Michael Gnant, Werner Kwasny, Christoph Tausch, Leonore Handl-Zeller, Brigitte Pakisch, Susanne Taucher, Josef Hammer, Gero Luschin-Ebengreuth, Marianne Schmid, Felix Sedlmayer, Michael Stierer, Georg Reiner, Karin Kapp, Friedrich Hofbauer, Andrea Rottenfusser, Sabine Pöstlberger, Karin Haider, Wolfgang Draxler, Raimund Jakesz
  [show abstract] [hide abstract]
  ABSTRACT: In women with favorable early breast cancer treated by lumpectomy plus tamoxifen or anastrazole, it remains unclear whether whole breast radiotherapy is beneficial. Between January 1996 and June 2004, the Austrian Breast and Colorectal Cancer Study Group (ABCSG) randomly assigned 869 women to receive breast radiotherapy +/- boost (n = 414) or not (n = 417) after breast-conserving surgery (ABCSG Study 8A). Favorable early breast cancer was specified as tumor size <3 cm, Grading 1 or 2, negative lymph nodes, positive estrogen and/or progesterone receptor status, and manageable by breast-conserving surgery. Breast radiotherapy was performed after lumpectomy with 2 tangential opposed breast fields with mean 50 Gy, plus boost in 71% of patients with mean 10 Gy, in a median of 6 weeks. The primary endpoint was local relapse-free survival; further endpoints were contralateral breast cancer, distant metastases, and disease-free and overall survival. The median follow-up was 53.8 months. The mean age was 66 years. Overall, there were 21 local relapses, with 2 relapses in the radiotherapy group (5-y rate 0.4%) vs. 19 in the no-radiotherapy group (5.1%), respectively (p = 0.0001, hazard ratio 10.2). Overall relapses occurred in 30 patients, with 7 events in the radiotherapy group (5-y rate 2.1%) vs. 23 events in the no-radiotherapy group (6.1%) (p = 0.002, hazard ratio 3.5). No significant differences were found for distant metastases and overall survival. Breast radiotherapy +/- boost in women with favorable early breast cancer after lumpectomy combined with tamoxifen/anastrazole leads to a significant reduction in local and overall relapse.
  International Journal of Radiation OncologyBiologyPhysics 07/2007; 68(2):334-40. · 4.11 Impact Factor
• Article: Progress in Radio-Oncology VIII

  Peter Lukas, Karin Kapp, Richard Pötter, Felix Sedlmayer
  Strahlentherapie und Onkologie 01/2007; 183:1-2. · 3.56 Impact Factor
• Article: Irradiation with and without Razoxane in the Treatment of Incompletely Resected or Inoperable Recurrent Rectal Cancer

  Walter Rhomberg, Josef Hammer, Felix Sedlmayer, Helmut Eiter, Dieter Seewald, Barbara Schneider
  [show abstract] [hide abstract]
  ABSTRACT: Background and Purpose:In an earlier phase II study, irradiation together with razoxane was shown to improve local control in recurrent rectal cancer. Therefore, the Austrian Society of Radiooncology (ÖGRO) initiated a randomized controlled trial in 1992 to compare this combined treatment versus radiation therapy alone. Patients and Methods:Between 1992 and 1999, 36 patients with localized recurrences of rectal cancer were randomized to receive radiotherapy without (group A) or with razoxane (group B). The prognostic variables of the two groups were similar except for a longer median latency period from initial surgery to local recurrence in group A. High-energy photons with daily fractions between 170 and 200 cGy were used. The median total radiation dose was 60 Gy in each group. The patients in group B received a median razoxane dose of 9.6 g (range, 5–12 g). Main outcome measures were local control, overall survival, and toxicity. Results:The combined treatment with razoxane increased the local control rate compared to radiotherapy alone (39% vs. 8%; p = 0.05). The median survival time was not different between the groups (20 months each). No patient in arm A but four of 18 patients in arm B survived 5 years. Acute toxic effects were of moderate degree in both groups. There were no substantial differences as to late side effects. Conclusion:Radiotherapy together with razoxane is superior to radiation treatment alone in recurrent rectal cancer as far as local control is concerned. In some patients, long-term survival was achieved with razoxane and radiotherapy. Hintergrund und Ziel:Die Kombination von Radiotherapie und Razoxan zeigte in früheren Studien bei Lokalrezidiven von Rektumkarzinomen eine hohe lokale Kontrollrate und verbesserte Überlebenszeiten. Daher wurde 1992 von der Österreichischen Gesellschaft für Radioonkologie (ÖGRO) eine randomisierte Studie begonnen, um diese Kombination mit einer alleinigen Bestrahlung zu vergleichen. Patienten und Methodik:Zwischen 1992 und 1999 wurden 36 Patienten mit inoperablen Rezidiven randomisiert und einer Strahlentherapie allein (Gruppe A) oder in Kombination mit Razoxan (Gruppe B) zugeteilt. Die mediane Strahlendosis betrug in beiden Gruppen 60 Gy, die tägliche Einzeldosis lag zwischen 170 und 200 cGy. Patienten der Gruppe B erhielten eine mediane Razoxandosis von 9,6 g (5–12 g). Die prognostischen Variablen waren in beiden Gruppen ähnlich verteilt mit Ausnahme der Latenzzeit von der Primärdiagnose bis zum Auftreten des Rezidivs (25 Monate vs. 12 Monate in Gruppen A und B). Studienendpunkte waren lokale Kontrolle, Gesamtüberleben und Verträglichkeit. Ergebnisse:Die lokale Tumorkontrolle betrug mit alleiniger Photonentherapie 8%, bei gleichzeitiger Gabe von Razoxan 39% (p = 0,05). Die mediane Überlebenszeit lag in beiden Gruppen bei 20 Monaten. In Gruppe A überlebte kein Patient 5 Jahre, in Gruppe B vier von 18 Patienten. Akute Nebenwirkungen der Grade 1–3 und Strahlenspätreaktionen waren in beiden Gruppen ähnlich verteilt. Schlussfolgerung:Radiotherapie zusammen mit Razoxan ist einer alleinigen Bestrahlung bezüglich lokaler Tumorkontrolle beim inoperablen Rezidiv des Rektumkarzinoms überlegen. Im Kombinationsarm fand sich häufiger ein Langzeitüberleben.
  Strahlentherapie und Onkologie 01/2007; 183(7):380-384. · 3.56 Impact Factor
• Article: Epidemiological aspects of hadron therapy: a prospective nationwide study of the Austrian project MedAustron and the Austrian Society of Radiooncology (OEGRO).

  Ramona Mayer, Ulrike Mock, Robert Jäger, Richard Pötter, Christian Vutuc, Helmut Eiter, Kristine Krugmann, Josef Hammer, Brigitte Hirn, Robert Hawliczek, [......], Elisabeth Nechville, Brigitte Pakisch, Michael Papauschek, Wolfgang Raunik, Walter Rhomberg, Hubert Sabitzer, Annemarie Schratter-Sehn, Felix Sedlmayer, Irene Wedrich, Thomas Auberger
  [show abstract] [hide abstract]
  ABSTRACT: The planned MedAustron hadron therapy facility is designed to compare proton and carbon ion beam therapy under the same technical conditions. For the calculation of the number of potential patients for hadron therapy so far, only epidemiological estimations on cancer incidence are available without inclusion of the percentage of patients routinely referred to conventional radiotherapy. Nationwide prospective survey to collect disease and treatment related data on patients receiving conventional radiotherapy at all 12 treatment facilities. Epidemiological cancer incidence (Statistic Austria 1999) were correlated with the number of patients receiving conventional radiotherapy. Based on published clinical and experimental results on proton and carbon ion therapy, a calculation of patient's subgroups suitable for hadron therapy was performed at five European University hospitals involved in the HICAT, CNAO, ETOILE and MEDAustron project. Using the mean values of the University specific percentages per tumour site, the number of potential patients was estimated. In Austria, a total of 3783 patients started radiotherapy during the study period of 3 months resulting in an approximated number of 15132 patients per year. The number of potential patients was estimated to 2044 per year, representing 5.6% of all newly diagnosed cancer patients and 13.5% of all irradiated cancer patients. There is a clear place for a hadron therapy facility in Austria, based on pattern of care in radiotherapy, cancer incidence and indications.
  Radiotherapy and Oncology 01/2005; 73 Suppl 2:S24-8. · 5.58 Impact Factor
• Article: The med AUSTRON/OGRO patterns of care study on radiotherapy indications in Austria.

  Ulrike Mock, Ramona Mayer, Richard Potter, Robert Jäger, Christian Vutuc, Helmut Eiter, Josef Hammer, Robert Hawliczek, Brigitte Hirn, Tomas-Henrik Knocke-Abulesz, [......], Elisabeth Nechville, Brigitte Pakisch, Michael Papauschek, Wolfgang Ing Raunik, Walter Rhomberg, Hubert Sabitzer, Annemarie Schratter-Sehn, Felix Sedlmayer, Irene Wedrich, Thomas Auberger
  [show abstract] [hide abstract]
  ABSTRACT: In Austria a national survey was conducted by Med AUSTRON/Osterreichische Gesellschaft for Radio--Onkologie, Radiobiologie und Medizinische Radiophysik (OGRO) in order to estimate the indications, patient numbers and radiotherapy treatment planning procedures and performances at all Austrian radiotherapy institutes. Results were correlated with incidence rates (Austrian cancer registry) to determine patterns of radiotherapy practice in Austria. At 12 radiotherapy departments of Austria data of all patients receiving irradiation within a 3 months (2002/2003) period were assessed. On the basis of a questionnaire number of treated patients, indications, and parameters of disease (stage, histology) and treatment modalities were evaluated. Results were analysed with regard to different tumour groups, according to academic and non academic hospitals, and correlated with epidemiological data on cancer incidence. In total, 3783 patients were registered within this period. According to the different tumour entities percentages of patients receiving radiotherapy within initial treatment varied from 3% to 90 % (e.g. brain tumours: 77%, breast cancer: 90%, prostate cancer: 35%). The most frequent indications to radiotherapy per radiotherapy department were breast cancer (range 22%-35%; mean 26%), urological tumours (range 6%-27%; mean 12%) and bone metastases (mean 10%, range 3%-17%). In Austria breast cancer, urological tumours and bone metastases are representing the most common indications to radiotherapy. Among the different departments variations in indications to radiotherapy were observed. Our study is the first evaluation of radiotherapeutic management in Austria.
  Radiotherapy and Oncology 01/2005; 73 Suppl 2:S29-34. · 5.58 Impact Factor